Jazz Pharmaceuticals PLC (JAZZ) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

Total Assets Chart for Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC (JAZZ) total assets for FY2025 were USD 11.7B, a -2.9% change from FY2024. Jazz Pharmaceuticals PLC's total assets grew from USD 164.8M in 2005 to USD 11.7B in 2025 (6975.7% over 20 years). Total assets compound annual growth rate: 5-year CAGR of 12.3%, 10-year CAGR of 13.2%, 20-year CAGR of 23.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$15.02B
Implied Share Price
$231.39
Enterprise Value
$17.47B
Revenue (TTM)
$4.60B
EBITDA
$1.93B
Profit Margin
20.45%
Trailing P/E
16.18
Forward P/E
10.89
Price/Book (MRQ)
3.25
Price/Sales (TTM)
3.26
EV/EBITDA
11.03
EV/Revenue
3.88
Dividend Yield
—
Book Value
$74.10
Free Cash Flow (FY2025)
$1.15B
Free Cash Flow Yield
7.63%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.